YayaNews LogoYaya Financial News
美股Neutral$NTRA

Natera outlines $2.85B-$2.91B 2026 revenue outlook backed by 31% growth ex true-ups (NASDAQ:NTRA)

Natera (NTRA) Q2 2026 earnings call highlights: record test volumes, Signatera catalysts, raised revenue guidance and margin outlook—read key takeaways now.

Financial news writer6 ViewsSource Seeking Alpha

YayaNews contributes financial news and market context through the YayaNews editorial workflow.

Natera outlines $2.85B-$2.91B 2026 revenue outlook backed by 31% growth ex true-ups (NASDAQ:NTRA)
Image Source: Seeking Alpha

Natera (NTRA) Q2 2026 earnings call highlights: record test volumes, Signatera catalysts, raised revenue guidance and margin outlook—read key takeaways now.

Natera outlines $2.85B-$2.91B 2026 revenue outlook backed by 31% growth ex true-ups (NASDAQ:NTRA) | Seeking Alpha

Earnings Call Insights: Natera (NTRA) Q2 2026

Management View

CEO Steve Chapman said, “We processed approximately 1,044,000 tests in the second quarter…setting a new company record,” and highlighted oncology momentum: “we processed 283,000 clinical MRD units…approximately 56%” year-over-year growth, with “the largest sequential increase to date.”

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Quick Insights

What is driving Natera's record revenue and volume growth?

Growth is powered by Signatera's FDA approval, NCCN guidelines adoption, major commercial investments, increased oncology and clinical test processing, and gains in women's health segment.

How sustainable is Natera's recent growth pace into 2027?

Management is positive on sustaining growth due to investment and adoption catalysts but cautions that Q2 volume was boosted by Q1 disruption and does not expect similar record-setting in the immediate quarters ahead. ASP step-up benefits are mostly expected in 2027.

What are the major margin and pricing risks facing Natera in 2026?

Margin pressure arises from launch-phase new products with unoptimized costs, though cost reduction projects are underway. Major ASP/profit upside from reimbursement and guideline changes are not included in 2026 guidance, being targeted for 2027.

Recommended For You

More

Trending News

See More

»

Disclaimer

Original YayaNews editorial coverage, published for informational purposes.

This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.

Share

Topics & Symbols

Topics & symbols

Continue Reading

Previous & next

Related Reading

Go to Channel